SVRA - NASDAQ
Savara Inc.
$5.25
+1.9%Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
At a Glance
Live SnapshotNo Dividend Yield Data
SVRA has not reported any dividend yield values in the available annual periods.
No Dividend Payout Ratio Data
SVRA has not reported any dividend payout ratio values in the available annual periods.
No Net Dividends Paid Data
SVRA has not reported any net dividends paid values in the available annual periods.
Savara Inc. Dividend History
SVRA Dividend Payment History
| Declaration | Ex-Date | Payment Date | Dividend | Adjusted | Frequency | Growth |
|---|---|---|---|---|---|---|
| No dividend payment history available | ||||||
Savara Inc. Payout Ratio Analysis
Dividend Sustainability Analysis
Payout Ratio
Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.
FCF Payout Ratio
Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.
Sustainability
Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.
Related Guides
Continue your SVRA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.